Download PDF
Pharmacopsychiatry 1982; 15(3): 95-96
DOI: 10.1055/s-2007-1019516
© Georg Thieme Verlag KG Stuttgart · New York

Bromperidol Maintenance in Schizophrenia*

Bromperidol Erhaltungstherapie bei schizophrenen PatientenJ. P. McEvoy , W. H. Wilson , T. A. Ban , J. O. Brannen , S.  Berney
  • Vanderbilt University, Department of Psychiatry and Tennessee Neuropsychiatric Institute, Clinical Research Service, 1501 Murfreesboro Road, Nashville, Tennessee 38217, USA
* Drugs for this study were provided by Ortho Pharmaceuticals, Inc. This project was funded in part by a grant-in-aid from Ortho Pharmaceuticals, Inc. Research facilities are supported in part under and agreement with the Tennessee Department of Mental Health and Mental Retardation. We would like to express our thanks to Mr. Olaf K. Fjetland, Jr. for his assistance in the data collection process of the study.
Further Information

Publication History

Publication Date:
13 March 2008 (online)

Also available at
  PDF Download  Permissions and Reprints

Abstract

Twenty-three patients who completed a four-week, double-blind, clinical trial of bromperidol versus haloperidol were treated with bromperidol for eight additional weeks in a continuation study. Over 87 percent of patients maintained their improved status or showed further improvement.

Extrapyramidal signs were frequent, but required discontinuation of treatment in only two patients.

Zusammenfassung

23 Patienten wurden in einem doppelblinden, sich über 4 Wochen erstreckenden Versuch entweder mit Bromperidol oder Haloperidol behandelt. Die Bromperidol-Behandlung wurde in einer Fortsetzungsstudie über weitere acht Wochen ausgedehnt. Dabei hielt die erreichte Remission bei 87 % der Patienten an bzw. verbesserte sich noch. Extrapyramidale Symptome waren häufig, führten aber nur bei 2 Patienten zu einem Therapieabbruch.